N/A
Completed N=10
Feasibility of Using SPECT/CT Imaging to Map Lymphatic Drainage Patterns in Prostate Cancer Patients
Source: ClinicalTrials.gov NCT01008969 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Feb 2012
Primary outcomePrimary: Percentage of Participants Successfully Completed 99mTc-sulfur Nanocolloid SPECT/CT Within 3 Hours After Injection — 100 Percentage of Participants
Summary
The purpose of this study is to develop a practice procedure for lymphatic drainage mapping with the intent of providing a new tool that could potentially be used for radiation treatment planning. High-risk prostate cancer patients who are scheduled to be treated with intensity-modulated radiotherapy (IMRT) may be eligible to enroll in this study. 99mTc-sulfur nanocolloid, a radiopharmaceutical ("tracer") will be injected by a urologist using transrectal ultrasound guidance (TRUS)at the UCSF Urology Clinic. Participants will then undergo SPECT/CT imaging at the UCSF Nuclear Medicine Clinic. This study will evaluate the feasibility of transporting patients to the Nuclear Medicine Clinic for imaging within 1-3 hours after administration of 99mTc-sulfur nanocolloid.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Successfully Completed 99mTc-sulfur Nanocolloid SPECT/CT Within 3 Hours After Injection |
100 | — |
| SECONDARY Percentage of Images With Detectable Sentinel Lymph Nodes (LNs) From 99mTc-sulfur Nanocolloid SPECT/CT Scans |
100 | — |
Eligibility Criteria
Inclusion Criteria
- Male
- Age ≥ 18 years
- Diagnosis of definitive high-risk prostate cancer
- Clinically eligible and scheduled for definitive IMRT treatment with pelvic lymph nodal radiation (not a study procedure)
- At least one of the following risk factors:
- Pathologically confirmed pelvic nodal involvement;
- Enlarged pelvic lymph nodes (greater than 1 cm in the short axis) visible on CT or MRI images, or
- Greater than 15% risk of lymph node involvement calculated using the equation: Risk of positive nodes (%) = (2/3) prostate specific antigen (PSA) + [(Gleason score - 6)] × 10]. This formula is used to estimate the pathologic stage of prostate cancer with preoperative prostate specific antigen (PSA) and Gleason score, and adopted by many radiation oncology clinics, including our own radiation oncology physicians.
- Ability to give written informed consent and willingness to comply with the requirements of the protocol
Exclusion Criteria
- Any condition that compromises compliance with the objectives and procedures of this protocol, as judged by the principal investigator
Data sourced from ClinicalTrials.gov (NCT01008969). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.